Clinical Trial Update: A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing 12 mg paliperidone extended-release tablets manufactured at two sites (Gurabo and Vacaville) in schizophrenia patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Invega Paliperidone Extended Release 12 mg (Paliperidone)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED